Reference Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Ref Type
PMID
Authors Drew W. Rasco, Ryan J. Sullivan, Nehal J. Lakhani, Sanjeeva Reddy, Niranjan Sathyanarayana Rao, Louis J. Denis, Anthony W. Tolcher, Keith Flaherty
Title ASN003, a highly selective BRAF and PI3K inhibitor: Preclinical and phase 1 clinical data in patients with advanced solid tumors
Journal Journal of Clinical Oncology
Vol
Issue
Date
URL http://abstracts.asco.org/199/AbstView_199_186123.html
Abstract Text J Clin Oncol 35, 2017 (suppl; abstr e14102)

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Treatment Approach
Gene Name Source Synonyms Protein Domains Gene Description Gene Role
Therapy Name Drugs Efficacy Evidence Clinical Trials
ASN003 ASN003 4 1
Drug Name Trade Name Synonyms Drug Classes Drug Description
ASN003 ASN-003|ASN 003 BRAF Inhibitor 20 PIK3CA inhibitor 18 PIK3CG inhibitor 8 ASN003 is a small molecule inhibitor of BRAF, PIK3CA, and PIK3CG, which may result in inhibition of cell proliferation and antitumor activity (J Clin Oncol 35, 2017 (suppl; abstr e14102)).
Gene Variant Impact Protein Effect Variant Description Associated with drug Resistance
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
BRAF V600X melanoma sensitive ASN003 Preclinical - Pdx Actionable In a preclinical study, melanoma patient derived xenograft (PDX) model harboring a BRAF V600 mutation demonstrated antitumor activity when treated with ASN003 (J Clin Oncol 35, 2017 (suppl; abstr e14102)). detail...